FDA Authorizes Tidepool Loop, an Automated Insulin Dosing App
The FDA authorized the Tidepool Loop, an algorithm that could be used to work with commercially available insulin pumps and…
FDA Authorizes Omnipod 5 for Ages 2+ in Children with Type 1 Diabetes
The FDA authorized the Insulet Omnipod 5, the world’s first tubeless, wearable system, for children 2+, using an algorithm that…
Tandem Diabetes Makes Managing T1D More Convenient
Tandem announced the FDA clearance of bolus insulin dosing from their t:connect® mobile app. Soon, individuals with the Tandem t:slim…
FDA Authorizes a Fourth Artificial Pancreas System
The FDA authorized the Insulet Omnipod 5, the world’s first tubeless, wearable system for people 6 and older, using an…
New Study Shows Kids 1+ Benefit from Artificial Pancreas Technology
A new paper published in the New England Journal of Medicine shows hybrid closed loop systems help children as young…
Artificial pancreas systems: Sleeping without fear
Research shows Artificial Pancreas Systems can help improve diabetes-related outcomes and lighten the burden of T1D. Even during sleep.
FDA Approves 7-day Infusion Set
Medtronic’s Extended Wear Infusion Set (EWIS) is the first infusion set approved for 7 days, a significantly longer duration; Currently,…
SFC Fluidics, a Breakthrough T1D Partner, Receives Breakthrough Device Designation
SFC Fluidics, a Breakthrough T1D partner, received a breakthrough device designation for its interoperable insulin delivery pod. How is it different? Find out here.
FDA Approves an Artificial Pancreas System for Children Aged 2-6 Years
The Food and Drug Administration (FDA) approved the Medtronic MiniMed 770G artificial pancreas system for use by children aged 2…
Tandem Control-IQ Improves T1D Management in Children Ages 6 and Up
A clinical trial at four pediatric diabetes centers in the United States has found that a new artificial pancreas system—which…
